Stockreport

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com
PDF Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s spe [Read more]